lymphoma s

34
Lymphomas S. Sami Kartı, MD, Prof.

Upload: bayard

Post on 20-Jan-2016

23 views

Category:

Documents


1 download

DESCRIPTION

Lymphoma s. S. Sami Kartı, MD, Prof. Conceptualizing lymphoma. neoplasms of lymphoid origin, typically causing lymphadenopathy. ALL. CLL. Lymphomas. MM. Neutrophils. AML. Myeloproliferative disorders. Myeloid progenitor. Eosinophils. Hematopoietic stem cell. Basophils. Monocytes. - PowerPoint PPT Presentation

TRANSCRIPT

Page 1: Lymphoma s

Lymphomas

S. Sami Kartı, MD, Prof.

Page 2: Lymphoma s

Conceptualizing lymphoma

neoplasms of lymphoid origin, typically causing lymphadenopathy

Page 3: Lymphoma s

ALLALL MM MM CLLCLL LymphomasLymphomas

Hematopoieticstem cell

Neutrophils

Eosinophils

Basophils

Monocytes

Platelets

Red cells

Myeloidprogenitor

Myeloproliferative disordersMyeloproliferative disordersAMLAML

Lymphoidprogenitor T-lymphocytes

Plasmacells

B-lymphocytes

nanaïïveve

Page 4: Lymphoma s

B-cell development

stemcell

lymphoidprogenitor

progenitor-B

pre-B

immatureB-cell

memoryB-cell

plasma cellplasma cell

DLBCL,FL, HL

ALL

CLL

MM

germinalgerminalcentercenterB-cellB-cell

maturenaiveB-cell

Page 5: Lymphoma s

Clinically useful classification

Diseases that have distinct• clinical features• natural history• prognosis• treatment

Biologically rational classification

Diseases that have distinct• morphology• immunophenotype• genetic features• clinical features

Classification

Page 6: Lymphoma s

Lymphoma classification (2001 WHO)

B-cell neoplasms precursor mature

T-cell & NK-cell neoplasms precursor mature

Hodgkin lymphoma

Non-HodgkinLymphomas

Page 7: Lymphoma s

A practical way to think of lymphoma

Category Survival of untreated patients

Curability To treat or not to treat

Non-Hodgkin lymphoma

Indolent Years Generally not curable

Generally defer Rx if asymptomatic

Aggressive Months Curable in some

Treat

Very aggressive

Weeks Curable in some

Treat

Hodgkin lymphoma

All types Variable – months to years

Curable in most

Treat

Page 8: Lymphoma s

Mechanisms of lymphomagenesis

Genetic alterations Infection Antigen stimulation Immunosuppression

Page 9: Lymphoma s

Epidemiology of lymphomas

5th most frequently diagnosed cancer in both sexes

males > females incidence

NHL increasing Hodgkin lymphoma stable

Page 10: Lymphoma s

Risk factors for NHL

immunosuppression or immunodeficiency

connective tissue disease family history of lymphoma infectious agents ionizing radiation

Page 11: Lymphoma s

Clinical manifestations Variable

severity: asymptomatic to extremely ill time course: evolution over weeks, months, or

years

Systemic manifestations fever, night sweats, weight loss, anorexia, pruritis

Local manifestations lymphadenopathy, splenomegaly most common any tissue potentially can be infiltrated

Page 12: Lymphoma s

Other complications of lymphoma

bone marrow failure (infiltration) CNS infiltration immune hemolysis or

thrombocytopenia compression of structures (eg spinal

cord, ureters) pleural/pericardial effusions, ascites

Page 13: Lymphoma s

Diagnosis requires an adequate biopsy

Diagnosis should be biopsy-proven before treatment is initiated

Need enough tissue to assess cells and architecture open bx vs core needle bx vs FNA

Page 14: Lymphoma s

Stage I Stage II Stage III Stage IV

Staging of lymphoma

A: absence of B symptomsB: fever, night sweats, weight loss

Page 15: Lymphoma s

Three common lymphomas

Diffuse large B-cell lymphoma Follicular lymphoma Hodgkin lymphoma

Page 16: Lymphoma s

Relative frequencies of different lymphomas

Hodgkinlymphoma

NHL

Diffuse large B-cell

Follicular

Other NHL

Non-Hodgkin Lymphomas

~85% of NHL are B-lineage

Page 17: Lymphoma s

Follicular lymphoma most common type of “indolent”

lymphoma usually widespread at presentation often asymptomatic not curable (some exceptions) associated with BCL-2 gene

rearrangement [t(14;18)] cell of origin: germinal center B-cell

Page 18: Lymphoma s

defer treatment if asymptomatic (“watch-and-wait”)

several chemotherapy options if symptomatic

median survival: years despite “indolent” label, morbidity

and mortality can be considerable transformation to aggressive

lymphoma can occur

Page 19: Lymphoma s

Diffuse large B-cell lymphoma

Page 20: Lymphoma s

Introduction

most common type of “aggressive” lymphoma

extranodal involvement is common cell of origin: germinal center B-cell

Page 21: Lymphoma s

Clinical presentation

Usually presents with one or more rapidly growing tumor masses involving nodal or extranodal sites

Not tender Usually not interfere organ function

except by compression

Page 22: Lymphoma s

Treatment

Chemotherapy Radiotherapy Chemotherapy + radiotherapy Autologous or allogeneic stem cell

transplantation in relaps or refractory cases

Page 23: Lymphoma s

Hodgkin lymphoma

Thomas Hodgkin(1798-1866)

Page 24: Lymphoma s

Classical Hodgkin Lymphoma

Page 25: Lymphoma s

Hodgkin lymphoma

cell of origin: germinal centre B-cell Reed-Sternberg cells (or RS variants)

in the affected tissues most cells in affected lymph node are

polyclonal reactive lymphoid cells, not neoplastic cells

Page 26: Lymphoma s

Reed-Sternberg cell

Page 27: Lymphoma s

RS cell and variants

popcorn celllacunar cellclassic RS cell

Page 28: Lymphoma s

A possible model of pathogenesis

germinalcentreB cell

transformingevent(s)

loss of apoptosis

RS cellinflammatory

response

EBV?

cytokines

Page 29: Lymphoma s

Histologic subtypes

Classical Hodgkin lymphoma nodular sclerosis (most common subtype) mixed cellularity lymphocyte-rich lymphocyte depleted

Page 30: Lymphoma s

Epidemiology

less frequent than non-Hodgkin lymphoma

overall M>F peak incidence in 3rd decade

Page 31: Lymphoma s

Associated (etiological?) factors

EBV infection smaller family size higher socio-economic status caucasian > non-caucasian possible genetic predisposition other: HIV? occupation? herbicides?

Page 32: Lymphoma s

Clinical manifestations

lymphadenopathy extranodal sites relatively uncommon

except in advanced disease “B” symptoms

Page 33: Lymphoma s

Treatment and Prognosis

Stage Treatment Overall 5 year

survival

I,II ABVD x 2-4 & radiation

80-90%

III,IV ABVD x 6-8 70-80%

Page 34: Lymphoma s

Long term complications of treatment

infertility MOPP > ABVD; males > females sperm banking should be discussed premature menopause

secondary malignancy skin, AML, lung, MDS, NHL, thyroid,

breast... cardiac disease